Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) closed at $678.42 up 1.73% from its previous closing price of $666.87. In other words, the price has increased by $1.73 from its previous closing price. On the day, 0.94 million shares were traded. REGN stock price reached its highest trading level at $679.83 during the session, while it also had its lowest trading level at $664.675.
Ratios:
For a deeper understanding of Regeneron Pharmaceuticals, Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.23 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.24. For the most recent quarter (mrq), Quick Ratio is recorded 3.95 and its Current Ratio is at 4.73. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on February 05, 2025, Upgraded its rating to Outperform and sets its target price to $834 from $762 previously.
On January 16, 2025, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $1130 to $738.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 01 ’24 when McCourt Marion sold 1,000 shares for $844.61 per share. The transaction valued at 844,610 led to the insider holds 12,931 shares of the business.
MARION E MCCOURT bought 1,000 shares of REGN for $844,610 on Nov 01 ’24. On Oct 01 ’24, another insider, RYAN ARTHUR F, who serves as the Director of the company, sold 100 shares for $1048.78 each. As a result, the insider received 104,878 and left with 17,582 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, REGN now has a Market Capitalization of 74168262656 and an Enterprise Value of 66533986304. As of this moment, Regeneron’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.72, and their Forward P/E ratio for the next fiscal year is 14.67. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.90. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.22 while its Price-to-Book (P/B) ratio in mrq is 2.53. Its current Enterprise Value per Revenue stands at 4.685 whereas that against EBITDA is 14.376.
Stock Price History:
The Beta on a monthly basis for REGN is 0.41, which has changed by -0.2959965 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, REGN has reached a high of $1211.20, while it has fallen to a 52-week low of $642.00. The 50-Day Moving Average of the stock is -2.44%, while the 200-Day Moving Average is calculated to be -25.53%.
Shares Statistics:
For the past three months, REGN has traded an average of 925.35K shares per day and 1063690 over the past ten days. A total of 107.80M shares are outstanding, with a floating share count of 105.40M. Insiders hold about 3.59% of the company’s shares, while institutions hold 86.34% stake in the company. Shares short for REGN as of 1740700800 were 2565723 with a Short Ratio of 2.77, compared to 1738281600 on 2187734. Therefore, it implies a Short% of Shares Outstanding of 2565723 and a Short% of Float of 2.48.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
